EC Number   |
Inhibitors |
Structure |
|---|
   1.14.14.25 | (3-oxa-8-azabicyclo[3.2.1]octan-8-yl)[8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methanone |
- |
   |
| 1.14.14.25 | (3-oxa-8-azabicyclo[3.2.1]octan-8-yl)[8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]methanone |
- |
|
| 1.14.14.25 | (4-benzyl-4-hydroxypiperidin-1-yl)([2,4'-bipyridin]-3-yl)methanone |
- |
|
| 1.14.14.25 | 1-[3-(3-oxa-8-azabicyclo[3.2.1]octane-8-carbonyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]-4H-1,2,4-triazol-1-ium |
- |
|
| 1.14.14.25 | 2-[5-methyl-1-(pyridine-4-carbonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-3-yl]benzonitrile |
- |
|
| 1.14.14.25 | 8-(1,3-oxazol-5-yl)-N-phenyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide |
- |
|
| 1.14.14.25 | clobenpropit |
complete inhibition |
|
| 1.14.14.25 | more |
generation of a series of imidazo[1,2-a]pyridine analogues that effectively inhibit cholesterol 24-hydroxylase (CYP46A1), synthesis and evaluation, overview |
|
| 1.14.14.25 | N-benzyl-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide |
- |
|
| 1.14.14.25 | shRNA |
knockdown |
|
